Proposal Summary


Investigator(s)

Submitter Cheku Dorji
Kuenden Statistical Services
Cheku Dorji Mail
Principal Investigator Dr Guru Prasad Dhakal
JDWNRH
Dr Guru Prasad Dhakal Mail
Co-Investigator(s) Mongal Signh Gurung
MOH
Mongal Signh Gurung Mail
Co-Investigator(s) Rinchen Bidha
BKF
Rinchen Bidha Mail


Title(s) and abstract

Scientific title Evidence Generation and Policy Advocacy for Inclusion of ABO-Incompatible Kidney Transplantation in Bhutan’s Patient Referral Guidelines: A Rapid Registry-Informed Mixed-Methods Policy Evidence Assessment
Public title Evidence Generation and Policy Advocacy for Inclusion of ABO-Incompatible Kidney Transplantation in Bhutan’s Patient Referral Guidelines: A Rapid Registry-Informed Mixed-Methods Policy Evidence Assessment
 
Background Chronic kidney disease (CKD) is a major global cause of illness, death, disability, and health spending, often progressing silently to end-stage kidney disease, which requires dialysis or transplantation to sustain life. Dialysis prolongs survival but not kidney function, demanding frequent sessions and lasting costs to patients, families, and health systems. Kidney transplantation is generally the preferred treatment for eligible patients, offering better survival and quality of life; despite a high upfront cost, its cumulative cost can be lower than years of dialysis. Living donor transplantation matters most where deceased-donor transplantation is limited, as in Bhutan. A major barrier is ABO blood-group incompatibility between donor and recipient. Once an absolute contraindication, ABO-incompatible (ABOi) transplantation is now feasible in selected patients through desensitisation and modern immunosuppression, though it is costlier and requires specialised centres. Bhutan refers transplant patients overseas, but its Patient Referral Guidelines do not yet cover ABOi transplantation, leaving patients with willing but incompatible donors on long-term dialysis. The Ministry of Health has proposed including ABOi transplantation, but approval remains pending over cost concerns. The policy question is comparative: funding ABOi transplantation raises short-term referral costs, but excluding it means recurring dialysis costs to the health system, patients, caregivers, and the economy. The relevant comparison is cost of action versus cost of inaction, alongside clinical benefit, equity, and sustainability. A grant-funded protocol therefore proposes a rapid, mixed-methods study (July-October 2026) estimating potential ABOi candidates, Bhutanese self-financed experience, indicative Indian hospital costs, cost-effectiveness, CKD risk factors, and survival outcomes, to inform the Ministry of Health, Ministry of Finance, Cabinet, and referral guideline revision.
Objectives The general objective is to assess the national need, clinical feasibility, cost implications, cost-effectiveness, cost of inaction, CKD risk factors, survival/status outcomes, and implementation safeguards related to ABO-incompatible living donor kidney transplantation in Bhutan. Specific Objectives Specific Objectives 1. To describe the profile and survival/status of CKD and KRT patients in the BKF registry and dialysis centre records, and estimate the number of potential ABOi transplant candidates, including those who have already undergone ABOi transplantation abroad. 2. To estimate and compare the costs of ABO-compatible transplantation, ABOi transplantation and continued dialysis over one-, five- and ten-year horizons, using indicative estimates from selected Indian transplant hospitals. 3. To assess the cost-effectiveness (QALY/DALY) and fiscal and budget impact of including ABOi transplantation under government support. 4. To engage clinicians, policymakers, patients, caregivers, referral authorities and finance stakeholders to identify policy barriers, implementation requirements and safeguards.
Study Methods This is a rapid, registry-informed mixed-methods policy evidence assessment combining quantitative and qualitative approaches, to be completed within July-October 2026. It is pragmatic and policy-oriented rather than a full epidemiological study: where local data are incomplete, it uses transparent assumptions, published evidence, and sensitivity analysis. The work is organised into eight components. Component 1 is a rapid evidence review of international clinical, economic, and policy evidence on ABO-incompatible (ABOi) transplantation, plus a review of Bhutan's Patient Referral Guidelines and the stalled Ministry of Health proposal. Component 2 uses the BKF registry and dialysis centre records to profile known CKD/kidney replacement therapy patients, establishing the denominator for need estimation. Component 3 applies a transplant cascade, from all known CKD patients down to potential ABOi transplant candidates, based on transplant suitability, donor availability, and blood-group incompatibility. Component 4 documents Bhutanese patients who have self-financed ABOi transplants abroad, capturing cost, financing, and outcomes descriptively. Component 5 conducts cost, budget-impact, and QALY/DALY-based analysis, comparing cost of action versus cost of inaction across scenarios of one, three, five, and ten cases per year, at conservative, base-case, and high-cost levels. Component 6 analyses survival and vital status using registry dates, applying Kaplan-Meier and Cox methods only if data completeness allows. Component 7 covers stakeholder consultation with MoH, MoF, NMS, JDWNRH, dialysis centres, BKF, patients, and caregivers, using thematic analysis to identify policy barriers and safeguards.
Expected outcomes and use of results Expected outputs: the final protocol and ethics package, data collection tools, and a cleaned analytical dataset, alongside the rapid evidence review, the BKF registry and dialysis centre patient profile, the ABO-incompatible (ABOi) transplant needs estimate, self-financed ABOi case documentation, Indian hospital cost assessment, cost and fiscal impact analysis, cost-of-action versus cost-of-inaction comparison, indicative QALY/DALY analysis and stakeholder consultation findings. These feed into a technical report, a policy brief, and a policy dialogue presentation. Policy use: the findings will support evidence-informed deliberation on whether to include ABOi transplantation in Bhutan's Patient Referral Guidelines. Rather than a single yes/no recommendation, the study will present a menu of options: no inclusion at this stage, inclusion only for highly selected patients, phased pilot inclusion with a fixed annual ceiling, inclusion with negotiated package rates and approved hospitals, or full inclusion subject to annual review. Recommended safeguards accompanying inclusion may cover confirmed ESKD, formal transplant suitability assessment, a willing related donor, documented ABO incompatibility, review by a national clinical committee, referral restricted to approved hospitals, negotiated rates, cost ceilings, mandatory follow-up reporting, and annual expenditure and outcome review.
 
Keywords chronic kidney disease; end-stage kidney disease; kidney replacement therapy; dialysis; kidney transplantation; ABO-incompatible transplantation; living donor transplantation; cost of inaction; budget impact; QALY; DALY; case-control study; survival analy


Research Details

Student research No
Start Date 15-Sep-2026
End Date 15-Dec-2026
Key Implementing Institution Bhutan Kidney Foundation
Multi-country research No
Nationwide research Yes
Research Domain(s) Non-communicable diseases & Healthy Lifestyles
Research field(s) Non-communicable Disease
Involves human subjects Yes
  Population-Based Survey
Data Collection Primary and secondary data
Proposal reviewed by other Committee No